Trial design, analysis, and expansion; including patient selection, synthetic control arms, experimental vs. SoC benefit assessment
Test multiple drug scenarios in thousands of patient tumors, capturing morphology, microenvironment, spatial metabolism at a fraction of the time/cost of traditional studies
Most of us have experienced the pain of a friend or family member’s cancer diagnosis and treatment in our lives. The process of diagnosis, treatment and monitoring — and the resulting uncertainty — has a debilitating impact. At SimBioSys, we…
Abstract: What would you do if you knew everything about a patient’s tumor? How should a physician make a treatment decision with multi-omics and imaging data at single-cell resolution? We sought to answer these questions by constructing a deterministic, 4-D,…
Abstract: Metabolism is an important regulator of cancer behavior. The extent to which patient-to-patient variability in tumor metabolism influences patient prognosis, however, remains unclear. We addressed this question by developing an approach to simulate cancer metabolism that integrates RNA-seq data…
Background: Despite substantial advances in the understanding of breast cancer biology, the decision to use NACT for EBC is based on tumor size, lymph node status, and subtype. Even with aggressive therapy, the majority of women will not achieve a pathologic…
John Cole, Co-Founder & Chief Scientific Officer of Research Park startup SimBioSys, joins the podcast! He discusses the breakthroughs his team has created for “transforming decision making and patient experience in cancer care” through a powerful software platform. Tune in…
Each week, staff writer Paul Wood interviews a high-tech difference-maker. This week, meet TUSHAR PANDEY, chief executive officer at SimBioSys Inc. in the University of Illinois Research Park. The company is working on technology to allow doctors and scientists to look…
Background: Although metabolic disfunction is one of the hallmarks of cancer and metabolism-based therapies are a key class of chemotherapeutics, there remains no systematic way to identify metabolism-based targets for therapeutic intervention. Because of this deficiency, metabolism-based therapies offer a…
Background: Over the last decade, there has been incredible progress in HER2-positive breast cancer patients with the adoption of targeted therapies like Trastuzumab and Pertuzumab to complement existing chemotherapies. Increasingly neoadjuvant therapy is the preferred method of therapy as it…
SOLUTIONS
RESOURCES
©SimBioSys